Given similar side effect profiles and the convenience advantage of weekly versus daily dosing, semaglutide has largely superseded liraglutide as the preferred GLP-1 option for most patients
2019;25(Suppl 2):1-75
More serious potential adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (especially with dehydration), and increased risk of hypoglycemia when used with insulin or sulfonylureas
The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls
Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism
Severe abdominal pain: Pain that is intense, persistent, or localized to one area needs assessment
